Trials / Completed
CompletedNCT00635128
Safety and Immunogenicity of a Booster Dose of GSK Biological's Boostrix-Polio Vaccine
Evaluation of GSK Biological's dTpa-IPV Booster Vaccine in Children and Adolescents, 5 Years After Previous dTpa-IPV Boosting.
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 415 (actual)
- Sponsor
- GlaxoSmithKline · Industry
- Sex
- All
- Age
- 9 Years – 13 Years
- Healthy volunteers
- Accepted
Summary
Subjects aged 9 to 13 years who participated in the 711866/001 study 5 years ago will be evaluated for immune persistence and will receive a combined dTpa-IPV booster dose that will be evaluated in terms of immunogenicity, safety and reactogenicity.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | Boostrix-Polio | A single booster dose of dTpa-IPV vaccine will be administered to all subjects. IM administration in the deltoid muscle of the non-dominant arm. |
Timeline
- Start date
- 2008-02-01
- Primary completion
- 2008-07-08
- Completion
- 2008-07-08
- First posted
- 2008-03-13
- Last updated
- 2018-06-06
- Results posted
- 2017-07-05
Locations
38 sites across 1 country: Germany
Source: ClinicalTrials.gov record NCT00635128. Inclusion in this directory is not an endorsement.